XML 40 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Geographic Information and Concentrations
 12 Months Ended
Dec. 31, 2022
Risks and Uncertainties [Abstract]  
Geographic Information and Concentrations GEOGRAPHIC INFORMATION AND CONCENTRATIONS
Revenues are attributed to geographical areas based on the location at which we earned revenue for product sales of IBSRELA or the domicile of our collaboration partners. A summary of our revenue by geographic areas for the years ended December 31, 2022, 2021 and 2020, is as follows (in thousands):
Year Ended December 31,
202220212020
United States (1)$15,600 $— $— 
International:
Asia Pacific (2)36,527 10,084 6,765 
North America (3)31 13 806 
Total revenue$52,158 $10,097 $7,571 
(1)Revenues from the United States are comprised of amounts earned from sales of IBSRELA.
(2)Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 KKC Agreement and the 2019 KKC Agreement.
(3)Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.
Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December 31, 2022, 2021 and 2020 were as follows:
Year Ended December 31,
202220212020
KKC70.0 %100 %89 %
Knight0.1 %— %11 %
AmerisourceBergen Drug Corporation11.1 %— %— %
Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses as of December 31, 2022 and 2021.